Chr Hansen Holding A/S (CPH:CHR) pending acquisition of the Lactobacillus rhamnosus-based LGG suite of probiotic strains from Finnish dairy group Valio will see it gain full rights on LGG including existing deals, a small production site in Finland as well as other dairy-focused specialty strains and a library of 3,200 strains.
The €73m acquisition of a library of 3,200 probiotic strains will open up opportunities in children’s immune health, Chr Hansen’s CEO says as the firm posts 13% profit growth from last year.
Stephen OHara, OptiBiotix Health Plc (LON:OPTI) CEO said: “Christian Hansen (one of the worlds largest probiotic manufacturers), acquisition of Valios’ LGG strain and strain library for €72m shows the value industry places on a single strain, a recognised brand, and supporting humans studies. OptiBiotix has an extensive strain library, supporting science, a brand (LP-LDL), a well understood mechanism of action, and multiple application opportunities in cholesterol reduction, cardiovascular risk, diabetes and bone health. With the launch of products next spring we would look to build revenues in multiple application areas and build value in our LP-LDL and other strains in our repository.”
